01—Abstract
Summary
Summary of the 10-Q filed November 9, 2016. Cited figures are marked; the original filing is the authoritative source.
Axon Enterprise, Inc. (formerly TASER International, Inc.) reported a strong financial performance for the nine months ended September 30, 2016, with net sales increasing by 31.2% to $186.2 milliona compared to the same period in 2015.
This growth was driven by robust performance in both the TASER Weapons segment (+24.7%b) and the rapidly expanding Axon segment (+60.0%). The Axon segment, which includes body cameras and Evidence.com, saw significant revenue increases, particularly from Evidence.com services which grew by 145.0%. Despite increased operating expenses, especially in Sales, General & Administrative (SG&A) which rose 61.6% primarily due to investments in sales and marketing for the Axon segment, the company maintained a healthy gross margin of 64.9% for the nine-month period.
Financially, the company ended the period with $102.5 millionc in cash, cash equivalents, and investments. However, net income decreased by $3.9 million to $11.0 million for the nine-month period, largely impacted by increased operating expenses and a higher effective tax rate.
The company also actively repurchased stock, spending $33.7 milliond in the first nine months of 2016. Management is focused on continued growth in the Axon segment and managing operational complexities, as indicated by the remediation efforts for identified material weaknesses in internal controls over financial reporting.
02—Key points
Key Highlights
- Net sales grew by 31.2% year-over-year to $186.2 million for the nine months ended September 30, 2016.
- The Axon segment demonstrated significant growth, with net sales increasing by 60.0% to $41.9 million for the nine months ended September 30, 2016, driven by Evidence.com services.
- Gross margin remained strong at 64.9% for the nine months ended September 30, 2016, indicating effective cost management relative to sales.
- Operating expenses increased substantially, with SG&A up 61.6% and R&D up 23.6%, reflecting strategic investments in growth and product development, particularly for the Axon segment.
- Cash and cash equivalents, along with short-term investments, totaled $102.5 million as of September 30, 2016, providing ample liquidity.
- The company repurchased $33.7 million of its common stock during the nine months ended September 30, 2016, signaling a return of capital to shareholders.
- A material weakness in internal controls over financial reporting was identified, related to the identification and recording of liabilities and revenue recognition, with remediation efforts underway.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q3 FY2016, Axon Enterprise, Inc. kept $0.05.
- Revenue$71.9M100.0%
- Cost of revenue−$25.3M35.2%
- Gross profit$46.6M64.8%
- Operating costs−$35.5M49.4%
- Operating income$11.1M15.4%
- Interest, other & tax−$7.2M10.1%
- Net income$3.8M5.3%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2016filed November 9, 2016Financial Statements
Q3 FY2016 against Q3 FY2015
| Line item | Q3 FY2016Q3 FY2015 | Change |
|---|---|---|
| Revenue | $71.88M$50.38M | +42.7% |
| Cost of Revenue | $25.32M$19.31M | +31.1% |
| Gross Profit | $46.56M$31.07M | +49.9% |
| R&D Expenses | $7.36M$6.53M | +12.7% |
| SG&A Expenses | $28.12M$17.83M | +57.7% |
| Operating Expenses | $35.48M$24.36M | +45.6% |
| Operating Income | $11.09M$6.71M | +65.3% |
| Net Income | $3.84M$1.52M | +152.7% |
| EPS (Basic) | $0.07$0.03 | +133.3% |
| EPS (Diluted) | $0.07$0.03 | +133.3% |
| Shares Outstanding (Basic) | 52.21M53.71M | −2.8% |
| Shares Outstanding (Diluted) | 53.14M54.69M | −2.8% |
05—Questions
Frequently Asked Questions
What is the primary driver of Axon Enterprise's revenue growth in this period?
The primary driver of revenue growth is the increasing adoption and sales within the Axon segment, which includes body-worn cameras and Evidence.com, a cloud-based digital evidence management system. Evidence.com services, in particular, saw substantial growth, contributing significantly to the segment's overall performance.
Why did net income decrease despite strong revenue growth?
Net income decreased for the nine months ended September 30, 2016, primarily due to a significant increase in operating expenses, particularly in Sales, General & Administrative (SG&A) costs and Research & Development (R&D). These investments are in support of the company's growth strategies, especially in the Axon segment. Additionally, a higher effective tax rate also impacted net income.
What is the significance of the identified material weakness in internal controls?
The material weakness identified relates to the timely and accurate recording of liabilities and revenue recognition. While remediation efforts are underway and expected to be completed by the end of fiscal year 2016, it indicates potential for misstatements in financial reporting. Investors should monitor the progress and effectiveness of these remediation efforts.
What is the company's strategy regarding stock repurchases?
Axon Enterprise has an active stock repurchase program. In the first nine months of 2016, the company repurchased approximately $33.7 million of its common stock. This reflects management's confidence in the company's value and its commitment to returning capital to shareholders, subject to market conditions.
06—Continue